CA 19-9 as a Marker for Gastrointestinal Cancers: A Review
Open Access
- 1 May 1998
- journal article
- review article
- Published by SAGE Publications in Annals of Clinical Biochemistry: International Journal of Laboratory Medicine
- Vol. 35 (3) , 364-370
- https://doi.org/10.1177/000456329803500304
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Tumor markers in patients with pancreatic carcinomaCancer, 1996
- A mechanism for inhibition of E-cadherin-mediated cell-cell adhesion by the membrane-associated mucin episialin/MUC1.Molecular Biology of the Cell, 1996
- Serum tumor markers for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitisGastroenterology, 1995
- Prognostic Value of Serum CA 19–9 Levels in Pancreatic AdenocarcinomaAnnals of Surgery, 1992
- Serum CA 19-9 and alpha-fetoprotein levels in primary hepatocellular carcinoma and liver cirrhosisCancer, 1991
- Comparison of CA 72–4 with CA 19–9 and Carcinoembryonic Antigen in the Serodiagnostics of Gastrointestinal MalignanciesScandinavian Journal of Gastroenterology, 1989
- Serum CA 19-9 concentrations and computed tomography findings in patients with pancreatic carcinomaCancer, 1986
- The clinical validity of circulating tumor-associated antigens CEA and CA 19-9 in primary diagnosis and follow-up of patients with gastrointestinal malignanciesJournal of Molecular Medicine, 1985
- Determination and significance of a new carbohydrate antigen CA19-9 in digestive system cancers.Japanese Journal of Medicine, 1985
- Initial clinical evaluation of an immunoradiometric assay for CA 19‐9 using the nci serum bankInternational Journal of Cancer, 1984